Lung Cancer Clinical Trial
The purpose of this study is to modify the surgical technique of VATS (video-assisted thoracoscopic surgery) lobectomy for early-stage non-small cell lung cancer.
| Status | Recruiting |
| Enrollment | 1000 |
| Est. completion date | December 2016 |
| Est. primary completion date | December 2016 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years and older |
| Eligibility |
Inclusion Criteria: 1. clinically diagnosed with stage I to stage II peripheral non-small cell lung cancer suitable for lobectomy. 2. signed informed consent from patient or legal representative, and allowed adequate follow-up. 3. operators must have experience of VATS lobectomy for more than 50 cases. Exclusion Criteria: 1. pregnant or breastfeeding women. 2. severe complications or infections. 3. no prior chemotherapy or radiotherapy for this malignancy. 4. medical history of mediastinal or hilar lymphadenopathy. 5. current participation in another study involving an investigational device or drug. |
Observational Model: Case Control, Time Perspective: Prospective
| Country | Name | City | State |
|---|---|---|---|
| China | Beijing Haidian hospital | Beijing | Beijing |
| China | Department of Thoracic Surgery, Center for Mini-invasive Thoracic Surgery, People's Hospital, Peking University | Beijing | Beijing |
| China | Department of Thoracic Surgery,Beijing Friendship Hospital | Beijing | Beijing |
| China | Department of Thoracic Surgery,Peking University School of Oncology | Beijing | Beijing |
| China | Department of Thoracic Surgery,Xuanwu Hospital Capital Medical University | Beijing | Beijing |
| China | Department of Thoracic Surgery,Jilin University Norman Bethune Hospital | Changchun | Jilin |
| China | Department of Thoracic Surgery, the second Xiangya Hospital of Central South University | Changsha | Hunan |
| China | Department of Thoracic Surgery, West China Hospital,Sichuan University | Chengdu | Sichuan |
| China | Department of Thoracic Surgery, Fuzhou General Hospital of Nanjing Military Command | Fuzhou | Fujian |
| China | Department of Thoracic Surgery,Fujian Provincial Hospital | Fuzhou | Fujian |
| China | Department of Thoracic Surgery,Fuzhou Pulmonary Hospital of Fujian | Fuzhou | Fujian |
| China | Department of Oncologic Surgery, Sun Yat-sen Univisity Cancer Center | Guangzhou | Guangdong |
| China | Department of Thoracic Surgery, Jiangsu Cancer Hospital | Nanjing | Jiangsu |
| China | Department of Thoracic Surgery,Zhongshan Hospital Fudan University | Shanghai | Shanghai |
| Lead Sponsor | Collaborator |
|---|---|
| Peking University People's Hospital | Beijing Friendship Hospital, Beijing Haidian Hospital, Central South University, First Hospital of Jilin University, Fujian Provincial Hospital, Fuzhou General Hospital, Fuzhou Pulmonary Hospital of Fujian, Jiangsu Cancer Institute & Hospital, Peking University, Shanghai Zhongshan Hospital, Sun Yat-sen University, West China Hospital, Xuanwu Hospital, Beijing |
China,
Li Yun, Wang Jun, Sui Xi-zhao, et al. Operative technique optimization in completely thoracoscopic lobectomy: Peking University experience: CHINESE JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY 2010;26(5).
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Operative time | For modified equipments group, if the operative time is significantly less than stand VATS group, the equipments is considered as feasible. | 6 weeks after surgery. | Yes |
| Primary | Survival time | overall survival rate(1-year, 3-year,5-year)will be analysed by the survival times of the follow-up patients. | 5 years | Yes |
| Primary | Hospital cost | less staples group vs.standard VATS group | 6 weeks after surgery. | No |
| Secondary | Quality of life | measured by Zubrod-ECOG-WHO score | 1 year | No |
| Secondary | Pain Scale Evaluation | measured by Visual analog scale (VAS) | 6 weeks after surgery | No |
| Secondary | Blood loss | to evaluate the blood loss volume as followed:open group vs. standard VATS group; modified equipments group vs. standard VATS group; less staples group vs.standard VATS group. | 3 months after surgery | Yes |
| Secondary | Postoperative mortality | to evaluate the postoperative mortality as followed: open group vs. standard VATS group; modified equipments group vs. standard VATS group; less staples group vs.standard VATS group. | 3 months after surgery | Yes |
| Secondary | Conversion rate | For modified equipments group, if conversion rates is not significantly different with stand VATS group, and success rate is over 90%, VATS lobectomy is considered as feasible. | 6 weeks after surgery | Yes |
| Secondary | Disease-free survival time | overall Disease-free survival rate(1-year, 3-year,5-year)will be analysed by the survival times of the follow-up patients. | 5 years after surgery | Yes |
| Secondary | Postoperative morbidity | to evaluate the postoperative morbidity above as followed: open group vs. standard VATS group; modified equipments group vs. standard VATS group; less staples group vs.standard VATS group. | 3 months after surgery | Yes |
| Secondary | Postoperative drainage duration | to evaluate the postoperative drainage duration as followed: open group vs. standard VATS group; modified equipments group vs. standard VATS group; less staples group vs.standard VATS group. | 3 months after surgery | Yes |
| Secondary | Postoperative hospital stay | to evaluate the postoperative hospital stay above as followed: open group vs. standard VATS group; modified equipments group vs. standard VATS group; less staples group vs.standard VATS group. | 3 months after surgery | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
| Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
| Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
| Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
| Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
| Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
| Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
| Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
| Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
| Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
| Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
| Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
| Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|